Last updated on January 2020

A Long Term Safety Study of S5G4T-1 in the Treatment of Papulopustular Rosacea


Brief description of study

To assess the safety of S5G4T-1 when applied once daily for 24 to 48 weeks in patients with papulopustular rosacea

Detailed Study Description

Patients from Phase 3 study may continue into an open label, long term safety extension. Patients will be admitted into the study only after a written informed consent has been obtained and not missing more than 1 visit of Visits 3, 4 or 5 in the phase 3 study. Eligible patients for enrollment will apply the study product, S5G4T-1, daily for up to 36 weeks to complete long term usage of the drug for 24 to 48 weeks.

Clinical Study Identifier: NCT03564145

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.